Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.
Beksac AT, Cumarasamy S, Falagario U, Xu P, Takhar M, Alshalalfa M, Gupta A, Prasad S, Martini A, Thulasidass H, Rai R, Berger M, Hectors S, Jordan J, Davicioni E, Nair S, Haines K 3rd, Lewis S, Rastinehad A, Yadav K, Jayaratna I, Taouli B, Tewari A. Beksac AT, et al. Among authors: jayaratna i. J Urol. 2018 Dec;200(6):1241-1249. doi: 10.1016/j.juro.2018.06.041. Epub 2018 Jul 3. J Urol. 2018. PMID: 30563651
Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
Falagario UG, Beksac AT, Martini A, Cumarasamy S, Gupta A, Prasad S, Thulasidass H, Shah QN, Jayaratna I, Lewis S, Rastinehad AR, Taouli B, Cormio L, Carrieri G, Tewari AK. Falagario UG, et al. Among authors: jayaratna i. J Urol. 2019 Jul;202(1):102-107. doi: 10.1097/JU.0000000000000134. Epub 2019 Jun 7. J Urol. 2019. PMID: 30730408
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer.
Mokkapati S, Porten SP, Narayan VM, Lim AH, Jayaratna IS, Roth B, Cheng T, Navai N, Wszolek M, Melquist J, Manyam G, Choi W, Broom B, Pretzsch S, Czerniak B, McConkey DJ, Dinney CPN. Mokkapati S, et al. Among authors: jayaratna is. Mol Cancer Res. 2020 Jun;18(6):811-821. doi: 10.1158/1541-7786.MCR-19-0766. Epub 2020 Mar 2. Mol Cancer Res. 2020. PMID: 32122956 Free article.
17 results